BOND-003 cohort P
58 evidence topics · 16 sources
Objective
Registry objective for Cohort P
Company description of the cohort's purpose
Population evaluated as presented at congress
Location and study date
Countries enrolling in Cohort P per registry
Registry dates for the whole BOND-003 study
| Field | Registry entry |
|---|---|
| Study start | “Study Start (Actual) 2020-10-27” |
| Primary completion | “Primary Completion (Estimated) 2030-06-16” |
| Study completion | “Study Completion (Estimated) 2031-12-24” |
Enrollment status reported in a 2025 trial-in-progress poster
Geographic distribution of enrolled participants
Study design
Single-arm, open-label design with intravesical administration
Registry design details
Response assessment schedule as stated in November 2026
Regulatory role of the cohort after FDA feedback, November 2026
Phase designation in the November 2026 investor presentation
Phase designation in company filings and releases
Eligibility criteria
Cohort P inclusion criteria
Key exclusion criteria shared by Cohorts C and P
Definition of BCG-unresponsive papillary disease as presented at congress
Treatment
Dose, transduction-enhancing agent, and schedule per registry
Induction, maintenance, and second induction courses
Study outcomes
Rationale for using high-grade event-free survival as the primary endpoint
Primary endpoint per registry and congress presentations
Primary endpoint per the Form 10-K description of the cohort
Definition of high-grade event-free survival used in the analysis
FDA recommendation for resected papillary disease
International Bladder Cancer Group recommendations for papillary disease
“Primary end points should include time to recurrence or recurrence-free survival (RFS) for fully resected papillary disease (because these patients have no evidence of disease at study entry)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with papillary disease that is BCG unresponsive, we consider recurrence-free rates of 30% at 12 months and 25% at 18 months as clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In scenarios where patients with CIS (with or without papillary disease) and papillary-only disease are evaluated separately, CR rate at 6 months and RFS, respectively, are appropriate primary end points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RFS in this setting includes death as an event and not a competing risk, distinct from low- and intermediate-risk NMIBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Benchmarks cited by the sponsor for BCG-unresponsive papillary disease
Secondary endpoints per registry
Secondary and additional endpoints per congress presentations
Statistical analysis description
Number of participants (Planned and analyzed)
Participants treated and evaluable at the September 2025 data cutoff
Efficacy population stated in the November 2026 investor presentation
| Field | Cretostimogene, BOND-003 Cohort P |
|---|---|
| Efficacy population | “N=54” |
Participants in the initial analysis, April 2025
Description of analysis sets
Kaplan-Meier estimation and censoring
Separate analysis of the two cohorts
Results
Participant disposition
Follow-up, re-induction, cystectomy, and treatment completion
“Median follow-up: 6.0 months” (opens the source at this quote in a new tab)
“8 patients were re-induced at 3 months” (opens the source at this quote in a new tab)
“No patients underwent RC” (opens the source at this quote in a new tab)
“No treatment related discontinuations” (opens the source at this quote in a new tab)
“98.2% received all protocol defined treatments” (opens the source at this quote in a new tab)
Baseline characteristics
Demographics and disease characteristics of the safety dataset
| Characteristic | n | % |
|---|---|---|
| Male | “44” | “78.6” |
| Female | “12” | “21.4” |
| Age, mean (SD), years | “71.6 (9.3)” | |
| Age, median (range), years | “74.0 (45-87)” | |
| Age < 65 years | “13” | “23.2” |
| Age ≥ 65 and < 75 years | “18” | “32.1” |
| Age ≥ 75 years | “25” | “44.6” |
| ECOG PS 0 | “48” | “85.7” |
| ECOG PS 1 | “8” | “14.3” |
| HG Ta at study entry | “33” | “58.9” |
| HG T1 at study entry | “23” | “41.1” |
| Prior BCG instillations, median (range) | “9.0 (5 – 21)” |
Efficacy results
High-grade event-free survival at the September 2025 data cutoff
Same estimates labeled as high-grade recurrence-free survival on the SUO 2025 slide
High-grade event-free survival by tumor stage
| Time point | HG Ta | HG T1 |
|---|---|---|
| 3 months | “92.8% (3 mo)” | “100% (3 mo)” |
| 6 months | “75.9% (6 mo)” | “100% (6 mo)” |
| 9 months | “75.9% (9 mo)” | “87.5% (9 mo)” |
Progression, cystectomy, and metastatic disease
Company report of the topline results
Twelve-month and 24-month estimates as of November 2026
| Time point | Cretostimogene, BOND-003 Cohort P |
|---|---|
| 3 months | “95.7 [95% CI: 83.8, 98.9]” |
| 6 months | “84.6 [95% CI: 68.6, 92.9]” |
| 9 months | “80.4 [95% CI: 62.3, 90.4]” |
| 12 months | “Not Yet Reached” |
Initial results in the first 24 treated participants, April 2025, superseded in December 2025
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events reported in more than 10% of participants
| Preferred term | Any grade, n (%) | Grade ≥ 3, n (%) |
|---|---|---|
| Participants with ≥1 TRAE | “40 (71.4%)” | “0 (0)” |
| Bladder spasm | “26 (46.4%)” | “0 (0)” |
| Dysuria | “22 (39.3%)” | “0 (0)” |
| Pollakiuria | “14 (25.0%)” | “0 (0)” |
| Urgency | “11 (19.6%)” | “0 (0)” |
Severity, serious events, deaths, and dosing interruptions
“Safety data cutoff as of 01SEP2025” (opens the source at this quote in a new tab)
“Most AEs were Grade 1-2” (opens the source at this quote in a new tab)
“0% Grade ≥ 3 TRAEs, Serious TRAE, deaths” (opens the source at this quote in a new tab)
“No dose delays, missed doses due to TRAEs” (opens the source at this quote in a new tab)
“No treatment related discontinuations” (opens the source at this quote in a new tab)
Safety summary in the Form 10-K
Study limitations
Summary: limitations of the Cohort P evidence
- Design: Cohort P is a single-arm, open-label cohort with no concurrent control. FDA guidance recommends a randomized, controlled design with a time-to-event endpoint for disease resected at or before trial entry and states that “Time-to-event endpoints are uninterpretable in a single-arm trial”.
- Maturity: all reported efficacy results come from one data cutoff (September 1, 2025), at a median follow-up of 6.0 months. Of 56 participants in the safety dataset, 51 were efficacy evaluable, and 5 censored participants were pending efficacy assessment. Twelve-month estimates were “Not Yet Reached” in the 2026 investor presentation, and the third-quarter 2026 results release expects 12-month data in December 2026.
- Publication status: the results have been reported in congress presentations, company filings, and press releases. No peer-reviewed publication of Cohort P was identified.
- Primary endpoint wording: the registry states a high-grade event-free survival endpoint (“all-cause High Grade Event Free Survival (HG-EFS)”), while one passage of the Form 10-K states that the primary endpoint “is overall event-free survival” and another passage of the same filing states that it “is HG-EFS”. The SUO 2025 slide labels the same three Kaplan-Meier estimates HG-RFS.
- Sample size: the registry target is 75 participants, while 56 participants were in the safety dataset at the data cutoff, and a 2025 trial-in-progress poster reported “Completed Enrollment”. The registry still lists Cohort P as open to enrollment. The 2026 investor presentation gives an efficacy population of “N=54”, against 51 efficacy-evaluable participants in the congress presentations.
- Inconsistent figures for the same data cutoff: the SUO 2025 podium reports 33 HG Ta (58.9%) and 23 HG T1 (41.1%) participants and one 2026 poster reports 8 re-induced participants; another 2026 poster reports 37 HG Ta (66.1%) and 19 HG T1 (33.9%) participants and 11 re-induced participants. The Form 10-K lists hematuria among the most common TRAEs, which the SUO 2025 table of TRAEs does not include.
- Regulatory role: company documents describe the cohort as “Phase 3”, as “an exploratory study”, and as “a Phase 2 cohort of BOND-003 and currently not intended for regulatory approval”. In its PIVOT-006 topline release, the company stated that, based on FDA feedback, the BLA would be broadened to include high-grade papillary-only disease.
- Generalizability: 96.4% of participants were enrolled in the US, 87.5% were White, and 85.7% had ECOG performance status 0. No health-related quality of life or patient-reported outcome results were identified.
- Comparisons: sponsor materials set Cohort P estimates beside results of other agents from separate trials; the investor presentation states that these data are not based on head-to-head or comparator studies.